Preprint Article: Automatic QSAR modeling of ADME properties: blood-brain barrier penetration and aqueous solubility

by Thanos Panagiotidis | Oct 15, 2009 | In Silico Modelling, Publications and presentations

Preprint Article: Automatic QSAR modeling of ADME properties: blood-brain barrier penetration and aqueous solubility This is a preprint of the article published in J Comput Aided Mol Des. 2008 Jun-Jul;22(6-7):431-40. Epub 2008 Feb 14. Abstract In this article, we...

Article: ADMET Property Prediction: The State of the Art and Current Challenges

by Thanos Panagiotidis | Oct 15, 2009 | In Silico Modelling, Publications and presentations

Article: ADMET Property Prediction: The State of the Art and Current Challenges This article was published in QSAR & Combinatorial Science, Volume 25, Issue 12, Pages 1172 – 1180 (DOI10.1002/qsar.200610093) AbstractIn this article, we review recent...

Article: Why is it still drug discovery?

by Thanos Panagiotidis | Oct 15, 2009 | General, Publications and presentations

Article: Why is it still drug discovery? Matthew Segall (while still in the ADMET Division, BioFocus DPI), explored the balance between luck and judgement in drug discovery. As Matt put it “The vision of an in silico design process for drug molecules is...

Improving Drug Discovery Efficiency via In Silico Calculation of Properties

by Thanos Panagiotidis | Oct 13, 2009 | Drug Discovery Applications, Publications and presentations

Improving Drug Discovery Efficiency via In Silico Calculation of Properties Dan Ortwine gave this presentation as part of a workshop at the ISSX North American meeting in Baltimore, MD, USA, 2009. The workshop, titled Effectively Using In Vitro Data, In Silico Models...

Poster: Guiding the Decision-Making Process to Identify High Quality Compounds

by Thanos Panagiotidis | Oct 13, 2009 | Drug Discovery Applications, Publications and presentations

Poster: Guiding the Decision-Making Process to Identify High Quality Compounds Defining a property profile is subjective and often leads to lengthy, interdisciplinary discussions about the criteria and their relevance. For example, is it worth sacrificing some potency...
« Older Entries

Recent Posts

  • Optibrium appoints Steve Yemm as Chief Commercial Officer
  • Introduction to StarDrop™
  • Real world case studies: Predicting pharmacokinetics from limited ADME data with deep learning
  • Inspyra™– Introduction
  • Cerella™– Introduction

Archives

Categories

  • Asteris
  • Cerella
  • Downloads
  • Drug Discovery Applications
  • Events
  • Example Code
  • General
  • In Silico Modelling
  • Latest Videos
  • Models
  • Multi-Parameter Optimisation
  • News
  • Ocura
  • Pipeline Pilot Protocols
  • Presentations and Webinars
  • Publications and presentations
  • Scoring Profiles
  • Scripts/Addons
  • StarDrop Hints and Tips
  • StarDrop Modules and Features
  • StarDrop Tutorials
  • Tutorials
  • Upcoming webinar
  • Videos
  • Webinars

Meta

  • Register
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

The Optibrium team works at the forefront of decision-analysis and predictive modelling research, developing innovative products that enhance the efficiency and productivity of drug discovery.

enquiries & support

General: [email protected]
StarDrop: [email protected]
Cerella: [email protected]
Press: [email protected]
Vacancies: [email protected]

  • Follow
  • Follow
further information

View our Privacy Policy

Copyright © 2023 Optibrium, Ltd. All Rights Reserved.
Optibrium™, StarDrop™, Augmented Chemistry®, Cerella™, Asteris™, Ocura™, Glowing Molecule™, WhichP450™, Auto-Modeller™, Nova™, MPO Explorer™ and Card View® are trademarks of Optibrium Ltd. Augmented Chemistry® is registered only in the UK and EU. Card View® is registered only in the United States. Matsy™ is a trademark of NextMove Software Ltd., BIOSTER™ is a trademark of iKem Szolgáltató és Kereskedelmi BT, Derek Nexus™ is a trademark of Lhasa Ltd., Surflex eSim3D is a trademark of BioPharmics LLC, and SeeSAR™ is a trademark of BioSolveIT GmbH. US Patent Numbers 9,224,098 and 9,367,812

Website designed and developed by Identity Creative.

Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}